CBCL201X2102C (#632)
Laufzeit: 01.01.2017 - 31.12.2019
imported
Kurzfassung
A phase Ib dose escalation study of BCL 201 in combination with Idelalisib in patients with Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
Laufzeit: 01.01.2017 - 31.12.2019
A phase Ib dose escalation study of BCL 201 in combination with Idelalisib in patients with Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
